Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143453 | 0.86 | PTGES (0.49) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL7148350 | 0.86 | PTGES (0.53) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL7143354 | 0.80 | BCHE (0.47) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL7146459 | 0.79 | PTGES (0.57) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL7147738 | 0.79 | ABCB1 (0.49) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL7143368 | 0.77 | AKR1B1 (0.65) | — | |
| SCHEMBL7143371 | 0.77 | AKR1B1 (0.65) | — | |
| SCHEMBL3615463 | 0.75 | MAOB (0.58) | MAOBMAOAALOX5L3MBTL1 | |
| SCHEMBL7148366 | 0.73 | ALDH1A1 (0.45) | MAOBMAOAPTGESALOX5PPARG | |
| SCHEMBL9143987 | 0.72 | FFAR1 (0.51) | MAOBMAOAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | MAOB 3505/4885MAOA 3492/4885PTGES 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.